SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for IMCR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
March 31, 2026 37.79M
December 31, 2025 42.58M
September 30, 2025 39.53M
June 30, 2025 43.30M
March 31, 2025 40.35M
December 31, 2024 41.93M
September 30, 2024 35.90M
June 30, 2024 38.68M
March 31, 2024 39.26M
December 31, 2023 41.81M
September 30, 2023 25.67M
June 30, 2023 35.12M
Date Value
March 31, 2023 32.86M
December 31, 2022 50.60M
September 30, 2022 13.71M
June 30, 2022 23.60M
March 31, 2022 26.96M
December 31, 2021 32.84M
September 30, 2021 27.62M
June 30, 2021 33.29M
March 31, 2021 27.83M
December 31, 2020 18.71M
December 31, 2019 11.03M

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Silence Therapeutics Plc 7.026M
NuCana Plc 2.113M
Mereo BioPharma Group Plc 4.012M
Compass Pathways Plc 16.40M
Genflow Biosciences Plc --